权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Identification of Immunomodulators for Diabetic Retinopathy Therapeutics

糖尿病视网膜病变治疗的免疫调节剂的鉴定

基本信息

批准号：
10132337
负责人：
Patricia R Taylor
金额：
$ 39.04万
依托单位：
CASE WESTERN RESERVE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-04-01 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10132337
关键词：
Address Autoimmune Autoimmune Diseases Background Diabetic Retinopathy Binding Biological Assay Blindness Blood Vessels Blood capillaries Blood-Retinal Barrier Cell Death Cells Chronic Complications of Diabetes Mellitus Cytokine Receptors Data Diabetes Mellitus Diabetic Retinopathy Diabetic mouse Diagnosis Endothelial Cells Epidemic Event Extravasation Gene Silencing Goals Health Human Immunoblot Analysis Immunomodulators In Vitro Inflammation Inflammatory Inflammatory Response Interleukin Receptor Interleukin-17 Interleukins Lasers Lead Lesion Leukocytes Link MAPK7 gene Mediating Modeling Muller&apos s cell Mus Neuroglia Oxidative Stress Pathogenesis Pathologic Pharmacology Phosphotransferases Photoreceptors Play Population Prediabetes syndrome Preventive therapy Procedures Production Proteins Reactive Oxygen Species Reporting Research Project Grants Retina Retinal Diseases Role Signal Pathway Signal Transduction Signaling Protein Steroids Streptozocin Stress Subcutaneous Injections TNF Receptor-Associated Factors TRAF4 gene TRAF6 gene Therapeutic Therapeutic Intervention Therapeutic Studies Transgenic Mice Treatment Cost Type 2 diabetic United States Vascular Permeabilities Vegf Inhibitor Vision Disorders Western World aging population clinically relevant cytokine diabetic early onset efficacy evaluation humanized monoclonal antibodies immunoregulation in vivo inhibitor/antagonist mouse model new therapeutic target novel therapeutics proliferative diabetic retinopathy receptor receptor expression small molecule inhibitor therapeutic target trait type I diabetic

项目摘要

ABSTRACT More than 9% of the US population has diabetes, with an additional 25% being treated for pre-diabetes, and this epidemic continues to rise annually. As diabetes progresses, >60% of Type II and >95% of Type I diabetics develop diabetic retinopathy; one of the leading causes of blindness in the working-age population worldwide. Currently, there are no preventative therapies to inhibit the asymptomatic chronic inflammation that slowly destroys retinal cells, which leads to vascular lesions and the onset of diabetic retinopathy. With such a significant impact on human health, new therapies are required to stay abreast of this diabetes complication. One of the most promising therapeutic targets lie within the inflammatory response, because inflammation can mediate much of the pathogenesis in diabetes complications. In a murine model of Streptozotocin (STZ)- induced-diabetes, we determined that diabetes mediated the production of Interleukin-17A (IL-17), one of the most prevalent cytokines associated with autoimmune and inflammatory pathogenesis. We also found that IL- 17 induced vascular permeability and capillary degeneration in the retina, which are hallmarks of non- proliferative diabetic retinopathy. Finally, we identified IL-17 receptor and the CIKS (Connection to IB Kinase and Stress activated protein) adaptor molecule constitutively expressed on multiple retina cells, which elicits retinal inflammation, oxidative stress, and the vascular lesions. The goal of this proposal is to unravel the IL-17 receptor/CIKS signaling events involved in retinal pathogenesis to reveal novel therapeutic targets for the early onset of diabetic retinopathy. We postulate that diabetes mediates a cascade of CIKS-TRAF (TNF Receptor Associated Factor) signaling events that initiate oxidative stress and retinal inflammation, which lead to vascular permeability and capillary degeneration in the retina. This is a precursor to the onset of proliferative diabetic retinopathy and vision loss. By using murine models of STZ-induced diabetes and ex vivo retina assays, we will identify the mechanism within the CIKS-TRAF signaling cascade that initiates retinal inflammation and pathogenesis. Through these studies therapeutic targets will be identified, which we postulate will delay the onset of diabetic retinopathy and inhibit vision loss.

摘要